Interim analysis results from the prospective, non-interventional study of ruxolitinib in patients with polycythemia vera (PAVE): safety results were consistent with previous findings
ONCOLOGY RESEARCH AND TREATMENT(2019)
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined